Development, Validation, and Application of an Imaging based CVD Scale

基于成像的 CVD 量表的开发、验证和应用

• 批准号: 9156582
• 负责人: PRASHANTHI VEMURI
• 金额: $ 53.86万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9156582
• 关键词: AD pathology; Accounting; Age; Aging; Alzheimer' s Disease; Amyloid; Anisotropy; Atrial Fibrillation; Autopsy; Biological Markers; Cerebrovascular Disorders; Clinic; Cognition; Communities; Complex; Data; Data Set; Dementia; Development; Diabetes Mellitus; Diagnosis; Dyslipidemias; Elderly; Ensure; Etiology; Evolution; Feedback; Functional disorder; Grant; Hypertension; Image; Impaired cognition; Infarction; Life Style; Location; Magnetic Resonance Imaging; Maps; Measures; Modeling; Nature; Nerve Degeneration; Outcome; Participant; Pathology; Patients; Physical activity; Positron-Emission Tomography; Prevention; Process; Quality of life; Risk Factors; Role; Sampling; Scheme; Smoking; Testing; Time; Validation; Weight; White Matter Hyperintensity; Work; amyloid pathology; apolipoprotein E-4; base; cerebrovascular; cerebrovascular lesion; cognitive function; cognitive performance; cohort; improved; population based; prospective; resilience; sex; success; tau Proteins; treatment planning; white matter

PROJECT SUMMARY / ABSTRACT Cerebrovascular Pathologies (CVP) and Alzheimer's disease (AD) pathologies (ADP) (amyloid and tau) are the two principal processes that drive cognitive impairment in the elderly. Even though CVP features have been available for decades, there is no scheme that integrates the multiplicity of CVD features into a metric that has predictive power comparable to the AD biomarkers and correlates with cognitive functioning. The primary objective of this grant is to develop and validate an imaging based metric for quantifying CVP which we call the “CVD scale” [CVD - Cerebrovascular Disease]. We will use a stepwise approach to develop several CVD scales based on incremental information going from simple to more complex MRI metrics - FLAIR (white matter hyperintensities (WMH), size and location of infarctions), T2* GRE (subcortical microbleeds), and DTI (Fractional anisotropy and mean diffusivity underlying WMH and surrounding WMH to measure white matter integrity). The models will be developed by weighting each of these imaging features according to their contribution to cognitive performance and the final CVD scale will be analytically selected based on its ability to predict cognition. We will use additional independent datasets to ensure the generalizability of our models and improve them if necessary. Since autopsy based scales for cerebrovascular lesions have not found to be predictive of cognition and/or difficult to evaluate antemortem, pathology outcomes will not be used for the development of the scale, but instead for confirmation. The secondary objective of the grant is to apply the CVD scale to understand a) the impact of sex, APOE4, and resilience measures (intellectual and physical activity lifestyle) on the evolution of CVP after accounting for traditional risk factors (diabetes, hypertension, dyslipidemia, atrial fibrillation, smoking), and b) investigate interactions between CVP and ADP. We will capitalize on the existing population-based and prospective Mayo Clinic Study of Aging (MCSA) cohort and acquire new imaging data (PIB PET, Tau PET, MRI) for the development of the CVD scale. The population- based nature of the MCSA sample is ideally suited for the development and generalizability of the scale because it captures the range of CVP. One of the strengths of the proposal is the planned dissemination of the CVD scale to the scientific community.

项目摘要/摘要